Received May 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | A3X2K | — |
received an extra Hep A/Extra Dose Administered; This non-serious case was reported by a nurse via call center representative and described the occurrence of extra dose administered in a 6-year-old male patient who received HAV (Havrix) (batch number A3X2K, expiry date 07-SEP-2026) for prophylaxis. Previously administered products included havrix (Patient received first dose on an unknown date) and Havrix (Patient received booster dose and completed the schedule for the first time on 06-SEP-2022). On 01-MAY-2025, the patient received the 3rd dose of Havrix. On 01-MAY-2025, an unknown time after receiving Havrix, the patient experienced extra dose administered (Verbatim: received an extra Hep A/Extra Dose Administered). The outcome of the extra dose administered was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 02-MAY-2025 Nurse stated that they had a patient that received a vaccine error. The patient received Hep A vaccine, Havrix and the patient had already received a Hep initial doses, the patient actually received an extra Hep A. Patient completed the schedule for the first time on September 6th, 2022. Patient received third dose of Havrix , which led to extra dose administered.